Tumor Immunology and Immunotherapy
Coordonnateur : Rees Robert C.
1. Adaptive T-cell immunity and tumor antigen recognition
2. Impact of aging and body mass on cancer immunotherapy outcomes
3. The potential of natural killer cells in cancer immunotherapy
4. The tumour microenvironment: the role of tumour associated macrophages in cancer progression and responses to therapy
5. "Hard" and "soft" loss of MHC class I expression in cancer cells
6. Modulation of the adaptive immune system through chronic inflammation and T-regulatory responses
7. Myeloid-derived suppressor cells: immune suppressive cells that facilitate tumor progression and promote and deter cancer-associated inflammation.
8. Triggering death receptors as a means of inducing tumoricidal activity
9. Identification of tumor antigens for clinical evaluation
10. Viral antigens as targets for prophylactic and therapeutic intervention in cancer
11. HER-2/neu as a target for vaccine and antibody directed therapies
12. Pre-clinical evaluation of immunotherapy: the case for prostate cancer and the tramp model
13. Tumor-associated antigens characterized in a conceptual framework of biology, microenvironment, and therapy
14. Predictive biomarkers to better select patients for cancer immunotherapy
15. Viral platforms for expression of tumour antigens in cancer immunotherapy
16. Translating research into clinical practice: lessons from the immunology and immunotherapy of haemopoietic malignancies
17. DNA vaccines
18. Programming the immune system through childhood infections: MUC1 Tumor Associated Antigen (TAA) as a Disease Associated Antigen (DAA)
19. Vaccination against myeloid leukaemias using newly defined antigens
20. Immune-checkpoint blockade in cancer immunotherapy
21. Multi-peptide cancer vaccines for clinical application
22. Adoptive T-cell therapy using TILs for the treatment of metastatic melanoma
23. Chimeric antigen receptor gene therapy in cancer
24. The vaccinal effect of monoclonal antibodies in cancer therapy
25. Antibody therapies: defining appropriate cell surface epitopes for targeting tumours
26. Adoptive lymphocyte (stem cell) therapy in cancer
27. Cancer Stem Cells (CSCs) and Epithelial-to-Mesenchymal Transition (EMT): Tumor Cell Plasticity Challenges Immunotherapy
28. Immune escape and aging of the immune system compromises the immune response to tumor antigens
Date de parution : 05-2014
Ouvrage de 470 p.
17.6x25.3 cm
Disponible chez l'éditeur (délai d'approvisionnement : 21 jours).
Prix indicatif 303,06 €
Ajouter au panier